Anti-platelet therapy: phosphodiesterase inhibitors. - Wikidata - thesis-toulmin - TriplyDB

Anti-platelet therapy: phosphodiesterase inhibitors.

Anti-platelet therapy: phosphodiesterase inhibitors.

http://www.wikidata.org/entity/Q27687228

about

BF066, a novel dual target antiplatelet agent without significant bleeding Natural Products for Antithrombosis Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential Antiplatelet and anti-proliferative action of disintegrin from Echis multisquamatis snake venom.Effects of phosphodiesterase 3A modulation on murine cerebral microhemorrhages Current antiplatelet treatment strategy in patients with diabetes mellitus.Mixed cerebrovascular disease and the future of stroke prevention.Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications Synthesis and Anti-Platelet Activity of Thiosulfonate Derivatives Containing a Quinone Moiety.Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions Targeting phosphodiesterases in anti-platelet therapy Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.Aspirin has limited ability to modulate shear-mediated platelet activation associated with elevated shear stress of ventricular assist devices.Antiplatelet agents in clinical practice and their haemorrhagic risk.Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.Brain regulation of thrombosis and hemostasis: from theory to practice.Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.Pharmacogenomics of oral antiplatelet drugs.Clinical efficacy and safety of cilostazol: a critical review of the literature.Protease receptor antagonism to target blood platelet therapies.Platelet-targeted pharmacologic treatments as anti-cancer therapy.Anti-platelet therapy in small animal medicine.Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications.Bioavailability of Alfrutamide and Caffedymine and Their P-Selectin Suppression and Platelet-Leukocyte Aggregation Mechanisms in Mice.Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, Block Ex Vivo Equid Herpesvirus Type-1-Induced Platelet Activation.Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis.Inhibition of adenosine diphosphate-induced platelet aggregation by alpha-lipoic acid and dihydroquercetin in vitro.Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%)Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats.Modulation of 3',5'-cyclic AMP homeostasis in human platelets by coffee and individual coffee constituents.Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).Cilostazol induces C-fos expression in the trigeminal nucleus caudalis and behavioural changes suggestive of headache with the migraine-like feature photophobia in female rats.Inhibition of Cyclic Adenosine Monophosphate-Specific Phosphodiesterase by Various Food Plant-Derived Phytotherapeutic Agents.Formulation of cilostazol spherical agglomerates by crystallo-co-agglomeration technique and optimization using design of experimentation.Human Cancer and Platelet Interaction, a Potential Therapeutic Target.Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System.Becatamide Found in Houttuynia cordata Suppresses P-selectin Expression Via Inhibiting COX Enzyme, Not Increasing cAMP in Platelets.Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.

P2860

Q27334889-A585A447-31FD-4225-85BF-D9D3B4F699BA Q28084934-594F2F24-2884-4FD6-89E2-EA9068FF9A1F Q29994589-F11F262A-CD1C-47F6-8AF5-A1B09D887F5F Q33619942-8B76A760-3E28-4F3D-BC55-0C949F0645E8 Q33768368-2A7D9EB9-5987-49D1-A436-01F612B574DA Q35544048-6411D4C9-E1DA-4533-A35F-2D7B663443F3 Q36025087-69696554-A150-46C4-A308-25FBDA73CD2E Q36460566-0C5F9F45-8F1D-49A0-B5B3-D943569F1DE5 Q36505025-D780562D-54B2-4DD2-ACA6-49B152665A76 Q36799847-599FBEB2-442C-49A9-8559-0B6A45524258 Q36929627-AA7A47F2-6FE9-4F20-98FD-14BF64538660 Q36972583-869FBA64-065C-4393-9867-E2E1D70705E9 Q37036154-C5B7D9D9-23C0-43E0-B1C5-919EB2F5DCFA Q37046266-9816B101-DBEF-42B6-B010-769F6E129202 Q37059195-6D3C6751-C703-463F-93F3-F202C74FBE81 Q38058760-F1E593CA-161E-458C-8F8F-DD9F25853269 Q38148437-BACB1D1A-369F-44E7-A742-45EFC4B08285 Q38166600-127DFC7C-A923-46A6-8FE7-A8B2E2577CEE Q38195628-0E27003D-ACF6-43C5-9DC3-AE39F7AC538B Q38372990-4CAB37E0-984D-4AF9-991D-14CE9F7400FD Q38616508-0D90C515-CB86-4386-9F49-421EA3F9663C Q38657846-F5DBB97A-5740-4819-819E-F2B5A5D4305F Q38770733-5302898E-CFA3-4454-8729-E515EDC06EAE Q39129014-5D0A0475-09D0-4FE1-8CE2-F66D544D66B2 Q40110524-2311912A-F396-411A-8416-8D2C89D4FF7E Q40426826-F426C7E0-0199-44D4-869E-548CADAB25F7 Q41166010-6D17C5E0-3C94-4894-AD79-49BC00430DBA Q41365399-0642CBF4-F61C-4910-A22F-C9B7B792F146 Q42069012-73A21F36-CECD-46FB-BDFA-B2AFFBF0C513 Q42372057-EE92E1E0-0741-4A5C-AD78-C80A01F56E3A Q43574589-03CA05B2-62A7-4958-9B41-27766B6EC8A9 Q46835111-C05FB732-AD75-4F87-88E7-112797E3ED12 Q47118227-68B4ED19-1A37-4AB7-81B6-D836F16964BC Q47627456-17D882EC-6BA0-4D90-BBD7-957CC8A44A7E Q47853676-FDD6B793-D159-423E-98AC-7F9234CBB737 Q52564509-EAAA0124-52DF-424A-92BA-E56AE91882EF Q52717949-529FFB1E-810B-4C30-83C9-2C4FFF86907B Q52809588-E438FE20-AB2F-441A-A144-EC6492213EBB Q53210327-8FB23945-3674-4A53-9B4E-ADE81B790F64 Q53689882-D19390FE-3B65-4960-9BC0-EDE0ADA48F4C

P2860

Anti-platelet therapy: phosphodiesterase inhibitors.

http://www.wikidata.org/entity/Q27687228

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Anti-platelet therapy: phosphodiesterase inhibitors.

@ast

Anti-platelet therapy: phosphodiesterase inhibitors.

@en

Anti-platelet therapy: phosphodiesterase inhibitors.

@nl

type

label

Anti-platelet therapy: phosphodiesterase inhibitors.

@ast

Anti-platelet therapy: phosphodiesterase inhibitors.

@en

Anti-platelet therapy: phosphodiesterase inhibitors.

@nl

prefLabel

Anti-platelet therapy: phosphodiesterase inhibitors.

@ast

Anti-platelet therapy: phosphodiesterase inhibitors.

@en

Anti-platelet therapy: phosphodiesterase inhibitors.

@nl

P1433

Q27687228-BF0D3DA0-2FAE-4CC3-A97C-2704749498BA

P1476

Q27687228-C428BA4E-9FCB-4496-A51F-4D98DA8E73CE

P2093

Q27687228-21DFBDD3-97FB-485D-84BE-FAD0611801DF

Q27687228-68CE2A0F-5D5A-40D8-A65F-E1CBE05C7823

Q27687228-BCAE3B1D-2001-4133-9505-7B81FCA564CE

P2860

Q27687228-04CC84BA-639E-4E3F-938F-A2F73275BC99

Q27687228-0FA987B1-05DF-4F3C-A3DB-F2E19ADD9293

Q27687228-1052EB4A-8384-49CC-B7D3-F2FCE17119F6

Q27687228-108365DC-20F4-46FA-80AE-F2D381369978

Q27687228-128ED332-6EB2-4B90-8C6C-D789933E4ABF

Q27687228-196FD94C-B16A-4987-BFB7-C72E4778A329

Q27687228-19FF1DAC-4FAC-49C4-BA9D-FFBA6F50F650

Q27687228-1ADFC85A-A5A5-4ED3-929F-78DCDC975F58

Q27687228-1B2ABCA8-3E8F-46C6-9240-094AAD5A530F

Q27687228-1DD91B94-2DF7-4C4E-916A-960087F8743B

P304

Q27687228-E97D73DD-BB32-4B3C-BB6E-9D2D24FA0350

P31

Q27687228-B8D7DDAD-780F-4EFD-AF3A-F9E1BF3C10BA

P3181

Q27687228-E4522166-7246-4A0D-91F2-47DD9D7C724B

P356

Q27687228-7136E4F2-D984-411C-B6A8-2ACD16B8D750

P407

Q27687228-C25C5709-8E85-498C-AB25-8583B03CF2B0

P433

Q27687228-4958E16A-9D03-4BF2-81D4-07A25AA6510D

P478

Q27687228-BBB8E839-FFD0-4D44-B3E6-69642B957D4D

P577

Q27687228-919757A7-313B-4F02-9630-7DE39BF8105E

P5875

Q27687228-8ABBB701-5073-4CB6-8524-62A0D6E3F262

P698

Q27687228-BD974874-AB9A-4A70-82C4-D1B28308491B

P932

Q27687228-4415D09E-BB60-4C43-83E2-9775D6B4E345

P3181

P356

J.1365-2125.2011.04034.X

P1433

British Journal of Clinical Pharmacology

P1476

Anti-platelet therapy: phosphodiesterase inhibitors.

@en

P2093

Emanuela Falcinelli

http://www.w3.org/2001/XMLSchema#string

Paolo Gresele

http://www.w3.org/2001/XMLSchema#string

Stefania Momi

http://www.w3.org/2001/XMLSchema#string

P2860

Dipyridamole for preventing stroke and other vascular events in patients with vascular disease

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves

RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome

Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination

Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

P304

634-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2015247

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/J.1365-2125.2011.04034.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51199048

http://www.w3.org/2001/XMLSchema#string

P698

21649691

http://www.w3.org/2001/XMLSchema#string

P932

3195739

http://www.w3.org/2001/XMLSchema#string